I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 25 studies | 30% ± 9% | |
| CD16-positive, CD56-dim natural killer cell, human | 14 studies | 32% ± 8% | |
| CD16-negative, CD56-bright natural killer cell, human | 9 studies | 25% ± 7% | |
| mature NK T cell | 8 studies | 22% ± 6% | |
| CD8-positive, alpha-beta T cell | 5 studies | 22% ± 5% | |
| retinal cone cell | 5 studies | 24% ± 5% | |
| astrocyte | 5 studies | 27% ± 9% | |
| deuterosomal cell | 4 studies | 48% ± 3% | |
| epithelial cell | 4 studies | 23% ± 6% | |
| GABAergic neuron | 4 studies | 32% ± 11% | |
| glutamatergic neuron | 4 studies | 46% ± 13% | |
| oligodendrocyte precursor cell | 4 studies | 22% ± 9% | |
| oligodendrocyte | 4 studies | 24% ± 5% | |
| endothelial cell | 3 studies | 25% ± 10% | |
| ciliated cell | 3 studies | 24% ± 7% | |
| transit amplifying cell | 3 studies | 30% ± 9% | |
| interneuron | 3 studies | 35% ± 16% | |
| neuron | 3 studies | 25% ± 5% | |
| gamma-delta T cell | 3 studies | 26% ± 5% |
